ERBB2 and breast carcinoma: Early studies demonstrated a synergistic effect between trastuzumab and chemotherapy [19], which led to the first clinical trials testing this combination, eventually resulting in trastuzumab approval in combination with chemotherapy in HER-2-overexpressing metastatic breast cancer [6] and later in early breast cancer [20] as well.